Epidemiological Study of a Prospective Cohort of Patients Aged 60 and Over Managed for Acute Myeloid Leukemia (AML) and Receiving Intensive Induction Therapy

Condition(s) studied

Study summary

This observational epidemiological study targets patients aged 60 and over with de novo or secondary acute myeloblastic leukemia suitable for intensive receive intensive induction therapy as defined by the group. The main aim of the study is to determine the epidemiological characteristics of AML patients, both clinically and biologically, and to correlate these to their outcome. The incidence of AML increases with age, exponentially after the age of 50, giving a median age at diagnosis of close to 70 years, with over half of patients half of patients are over 60 at diagnosis. The principle of treatment as in younger patients, is based on trying to achieve complete remission (CR). remission (CR). Observed complete remission rates range from 38 to 70%. Long-term survival of elderly subjects remains limited, at around 10 to 15%, despite the various types of consolidation tried out in recent years.

years. However, intensive chemotherapy remains the preferred option for initial treatment of these hematological diseases when general condition and comorbidities allow. As shown by Swedish registry studies, it is associated with improved life expectancy.

The proportion of patients who can receive intensive initial treatment is not well known in France, probably varies widely from one region to another, and certainly decreases with increasing age. Only the registry studies currently underway will enable us to assess this precisely.

Eligibility

Primary outcome measure(s)

• describe the initial characteristics of Acute myeloid leukemia (AML) in patients aged 60 years and older — at diagnosis (from first results related to AML until AML diagnosis) 3 months
  Values for leukocytosis, blasts, neutrophils, and platelets (in /mm3)
• describe the initial characteristics of Acute myeloid leukemia (AML) in patients aged 60 years and older — at diagnosis (from first results related to AML until AML diagnosis) 3 months
  the cytogenetic pronosis according ELN criteria
• Describe first line AML treatment received — 12 months
  type of treatment
• characterize the Overall survival (OS) — 5 years
  defined as the time from date of initiation of chemotherapy to date of death due to any cause. Patients still alive or lost to follow up will be censored at the time they were last known to be alive

Trial sites (27)

More French Innovative Leukemia Organisation trials in France

Other trials for the same condition